April 17, 2026 12:30 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls | 'Black law': Stalin burns copy of 'delimitation' bill, slams Modi govt | TCS halts Nashik BPO operations amid sexual abuse, conversion allegations | ‘We are surprised’: SC stays Pawan Khera’s bail over remarks on Himanta Biswa Sarma’s wife | Historic shift: Bihar gets first BJP CM as Samrat Choudhary takes oath | 'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping

Govt seeks details of Patanjali's COVID-19 remedy claim, halts it from advertising now

| @indiablooms | Jun 23, 2020, at 09:46 pm

New Delhi/IBNS: The Ministry of Ayush on Tuesday asked yoga guru Ramdev’s Patanjali Ayurved Ltd to provide details of the Ayurvedic medicine 'Coronil', which it has developed for the treatment of COVID-19, and to stop publicising or advertising the drug until the claims are duly examined.

Ramdev earlier in the day launched Ayurvedic medicine Coronil which he claimed will help in curing a patient of the infectious disease.

Taking cognizance of the news from media, the Ministry of Ayush stated that facts of the claim and details of the stated scientific study 'are not known to the Ministry.'

"The concerned Ayurvedic drug manufacturing company has been informed that such advertisements of drugs including Ayurvedic medicines are regulated under the provisions of Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder and the directives issued by the Central Government in the wake of COVID outbreak, " the ministry said in a statement.

The Ministry said that it sought details of the composition of the drug from Patanjali Ayurved based in Haridwar and until the results of the claim are verified, the company has been refrained from advertising the medicine.

"In order to make this Ministry aware of the facts of the aforesaid news and verify the claims,  Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for COVID-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results from data of the study (ies) and stop advertising/publicizing such claims till the issue is duly examined," the statement said.

"Ministry has also requested concerned State Licensing Authority of Uttrakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19," it added.

Launching the medicine earlier in the day from Haridwar, the company said that clinical control trials of the medicine were carried out adhering to standardized protocols and within the span of 3 to 15 days, all the COVID-19 positive patients transformed into negative ones without observing any mortality,  said reports.

According to reports, the medicine was launched after a research conducted jointly by the Patanjali Research Institute, Haridwar and the National Institute of Medical Science, Jaipur.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.